EP Patent

EP4062973A1 — 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation

Assigned to Shionogi and Co Ltd · Expires 2022-09-28 · 4y expired

What this patent protects

As a result of various studies on stabilizers to improve stability in water of a compound represented by formula (IA):or its pharmaceutically acceptable salt, it is possible to provide a solid preparation with good stability by containing any one or more of ascorbic acid or its d…

USPTO Abstract

As a result of various studies on stabilizers to improve stability in water of a compound represented by formula (IA):or its pharmaceutically acceptable salt, it is possible to provide a solid preparation with good stability by containing any one or more of ascorbic acid or its derivative, sulfur-containing amino acid or its derivative, sulfite or its derivative, citric acid or its derivative, and malic acid or its derivative.

Drugs covered by this patent

Patent Metadata

Patent number
EP4062973A1
Jurisdiction
EP
Classification
—
Expires
2022-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Shionogi and Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.